1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Haemophilus Influenzae Infections – Pipeline Review, H1 2013

Haemophilus Influenzae Infections – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 83 pages

Haemophilus Influenzae Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Haemophilus Influenzae Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Infections. Haemophilus Influenzae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Haemophilus Influenzae Infections.
- A review of the Haemophilus Influenzae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Haemophilus Influenzae Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Haemophilus Influenzae Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Haemophilus Influenzae Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Haemophilus Influenzae Infections 9
Haemophilus Influenzae Infections Therapeutics under Development by Companies 11
Haemophilus Influenzae Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Haemophilus Influenzae Infections Therapeutics - Products under Development by Companies 18
Haemophilus Influenzae Infections Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Haemophilus Influenzae Infections Therapeutics Development 21
Sanofi-Aventis 21
GlaxoSmithKline plc 22
Daiichi Sankyo Company, Ltd 23
Dainippon Sumitomo Pharma Co., Ltd. 24
Biological E. Limited 25
Novartis AG 26
Wockhardt Limited 27
LG Life Sciences, Ltd 28
Panacea Biotec Limited 29
Sinovac Biotech Ltd. 30
Serum Institute of India Limited 31
Haemophilus Influenzae Infections - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Hib Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
GSK-2189242-A - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Act-HIB reconstituted with TRIPACEL - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Haemophilus influenzae type b and meningococcal serogroup C (vaccine) + Priorix + Hiberix + Meningitec - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
GSK-217744 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
DTP-HepB-Polio-Hib - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
DTP-HepB-Polio-Hib - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
LBVF-0101 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
GSK-1024850A + GSK-2189242A - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
NU-300 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Easysix - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
GSK-2830930-A - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Vaxem Hib - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Second Generation Ketolides - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Trivalent Live-Attenuated Influenza Vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
GSK-2838500A - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
GSK-2838497A - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
GSK-2838501A - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Compound G-1 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
SM-295291 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
SM-369926 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Human Beta-Defensin-3 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
DTwP-HBV-HIB Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Compound-2a - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Haemophilus Influenzae Infections Therapeutics - Drug Profile Updates 69
Haemophilus Influenzae Infections Therapeutics - Dormant Products 74
Haemophilus Influenzae Infections - Product Development Milestones 76
Featured News and Press Releases 76
Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 76
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 76
Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 76
Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency 77
Dec 19, 2011: Viscogel Announces Publication Of Preclinical Results Of ViscoGel 78
Jun 15, 2011: Takeda To Initiate TAK-816 Phase III Clinical Trial In Japan 79
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 79
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 80
Sep 27, 1996: FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine 80
Jun 24, 1996: Connaught applies to FDA for licensing of first acellular pertussis vaccine to be used in combination with hib vaccine for infants 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83



List of Tables

Number of Products Under Development for Haemophilus Influenzae Infections, H1 2013 9
Products under Development for Haemophilus Influenzae Infections - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Development by Companies, H1 2013 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2013 20
Sanofi-Aventis, H1 2013 21
GlaxoSmithKline plc, H1 2013 22
Daiichi Sankyo Company, Ltd, H1 2013 23
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 24
Biological E. Limited, H1 2013 25
Novartis AG, H1 2013 26
Wockhardt Limited, H1 2013 27
LG Life Sciences, Ltd, H1 2013 28
Panacea Biotec Limited, H1 2013 29
Sinovac Biotech Ltd., H1 2013 30
Serum Institute of India Limited, H1 2013 31
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 37
Haemophilus Influenzae Infections Therapeutics - Drug Profile Updates 69
Haemophilus Influenzae Infections Therapeutics - Dormant Products 74
Haemophilus Influenzae Infections Therapeutics - Dormant Products (Contd..1) 75



List of Figures

Number of Products under Development for Haemophilus Influenzae Infections, H1 2013 9
Products under Development for Haemophilus Influenzae Infections - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Discovery and Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Route of Administration, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Molecule Type, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016’, provides in depth analysis ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...


Download Unlimited Documents from Trusted Public Sources

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

UTI - Investor Report, November 2016

  • November 2016
    39 pages
  • Anti-Infective  

  • United States  

View report >

Related Market Segments :

Infectious Disease

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.